

AMENDMENT TO THE CLAIMS

Applicants respectfully request that claims be amended without prejudice as follows.

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A method for purifying Interleukin-4 (IL-4) or muteins thereof comprising: (a) expressing the IL-4 or muteins thereof in a prokaryotic cell thereby forming inclusion bodies containing IL-4 or muteins thereof in said prokaryotic cell; (b) disrupting the prokaryotic cell to release the inclusion bodies; (c) separating the inclusion bodies from the cell debris; (d) solubilizing the inclusion bodies in a solution that includes a denaturing agent, thereby denaturing the IL-4 or muteins thereof; (e) separating the denatured IL-4 or muteins thereof using an immobilized metal chelate affinity chromatography (IMAC) system; ~~and (f) releasing the IL-4 or muteins thereof from the IMAC system; and (g) thereby obtaining a~~ renaturing the IL-4 or muteins thereof, thereby obtaining the purified IL-4 or muteins thereof.
2. (Previously presented) The method according to claim 1, wherein the step of separating the inclusion bodies further comprises the step of washing the inclusion bodies in a washing buffer capable of solubilizing lipids bound to the surface of the inclusion bodies or contained in cell wall fragments.
3. (Currently amended) The method according to claim 2, wherein the washing buffer ~~is a~~ comprises a non-ionic detergent, an ionic surfactant or a zwitterionic detergent.

4. (Currently amended) The method according to claim 2, wherein the washing buffer ~~for the inclusion bodies~~ is a buffer which maintains the pH between 7 and 10.
5. (Previously presented) The method according to claim 2, wherein the washing buffer additionally contains a chelating substance.
6. (Previously presented) The method according claim 5, wherein the chelating substance is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethyleneglycol-O,O' bis-(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA), nitriloacetic acid (NTA) and trans-1,2-diamino-cyclohexan-N'N,N',N'-tetraacetic acid (CDTA).
7. (Previously presented) The method according to claim 1, wherein the Interleukin-4 is IL-4 R121D Y124D.
8. (Previously presented) The method according to claim 1, wherein the renatured IL-4 or muteins thereof are obtained by dialysis, diafiltration or dilution.
9. (Previously presented) The method according to claim 8, wherein the dialysis, diafiltration or dilution is done in the presence of an artificial chaperone.
10. (Currently amended) The method according to claim ~~4~~9, wherein the artificial chaperone is a cyclic dextrin or linear dextrin.

11. (Previously presented) The method according to claim 1, wherein the prokaryotic host is *E. coli*.
12. (Previously presented) The method according to claim 1, wherein the IL-4 is mIL-4 Q116D Y119D.
13. (Previously presented) The method according to claim 1, wherein the step of separating the inclusion bodies is carried out by centrifugation.
14. (Previously presented) The method according to claim 1, wherein the solution used in the step of solubilizing the inclusion bodies comprises guanidinium salts.
15. (Cancelled)
16. (Cancelled)
17. (Previously presented) The method according to claim 1, wherein the step of separating the denatured IL-4 or muteins thereof with the IMAC system provides the IL-4 or muteins thereof having a purity of about 90% as estimated by SDS-PAGE analysis.
18. (Cancelled)

19. (Previously presented) The method according to claim 3, wherein the zwitterionic detergent is selected from the group consisting of CHAPS, CHAPSO, desoxycholate and the zwittergent series (N-alkyl-N,N-dimethyl-3-ammonio-1-propanesulfonate).
20. (New) A method for purifying Interleukin-4 (IL-4) or muteins thereof comprising: (a) expressing the IL-4 or muteins thereof in a prokaryotic cell thereby forming inclusion bodies containing IL-4 or muteins thereof in said prokaryotic cell; (b) disrupting the prokaryotic cell to release the inclusion bodies; (c) separating the inclusion bodies from the cell debris; (d) solubilizing the inclusion bodies in a solution that includes a denaturing agent, thereby denaturing the IL-4 or muteins thereof; (e) separating the denatured IL-4 or muteins thereof using an immobilized metal chelate affinity chromatography (IMAC) system; (f) renaturing the IL-4 or muteins thereof; and (g) releasing the IL-4 or muteins thereof from the IMAC system, thereby obtaining the purified IL-4 or muteins thereof.